These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31253398)

  • 1. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
    Chen Z; Yang H; Li Z; Xia Q; Nie Y
    Biochem Biophys Res Commun; 2019 Aug; 516(3):726-732. PubMed ID: 31253398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibition by TAK-228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models.
    Tang L; Fu Y; Song J; Hu T; Li K; Li Z
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00930. PubMed ID: 35142090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
    Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
    Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
    Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
    Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
    J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
    Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
    Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
    Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo.
    Vazakidou ME; Magkouta S; Moschos C; Psallidas I; Pappas A; Psarra K; Kalomenidis I
    Respirology; 2015 Nov; 20(8):1263-71. PubMed ID: 26245309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage.
    Xiong Y; Liu W; Huang Q; Wang J; Wang Y; Li H; Fu X
    Sci Rep; 2018 Aug; 8(1):11747. PubMed ID: 30082885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
    Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
    Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
    Rivera VM; Squillace RM; Miller D; Berk L; Wardwell SD; Ning Y; Pollock R; Narasimhan NI; Iuliucci JD; Wang F; Clackson T
    Mol Cancer Ther; 2011 Jun; 10(6):1059-71. PubMed ID: 21482695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
    Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C
    Cancer Res; 2012 Sep; 72(17):4483-93. PubMed ID: 22815528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.